These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27942097)

  • 1. Sociodemographic profiles and use-dynamics of Jadelle (levonorgestrel) implants in Jos, Nigeria.
    Pam VC; Mutihir JT; Nyango DD; Shambe I; Egbodo CO; Karshima JA
    Niger Med J; 2016; 57(6):314-319. PubMed ID: 27942097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Discontinuation of Subdermal Levonorgestrel Implants (Jadelle) at the Lagos University Teaching Hospital, Lagos, Nigeria: An Analytic Cohort Study.
    Ohazurike E; Olamijulo JA; Ibisomi L; Olorunfemi G; Oluwole AA
    Afr J Reprod Health; 2020 Jun; 24(2):48-63. PubMed ID: 34077091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Jadelle subdermal implants. Preliminary experience in a teaching hospital in the Niger Delta Region of Nigeria.
    Enyindah CE; Kasso T
    Niger J Med; 2011; 20(2):270-4. PubMed ID: 21970242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition from Norplant to Jadelle in a clinic with extensive experience providing contraceptive implants.
    Brache V; Faundes A; Alvarez F; García AG
    Contraception; 2006 Apr; 73(4):364-7. PubMed ID: 16531168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Jadelle used in Thai women aged between 20 and 45 years in King Chulalongkorn Memorial Hospital.
    Laphikanont W; Taneepanichskul S
    J Med Assoc Thai; 2006 Jun; 89(6):761-6. PubMed ID: 16850674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indications for removal of etonogestrel implant within two years of use in Jos, Nigeria.
    Mutihir JT; Nyango DD
    East Afr Med J; 2010 Nov; 87(11):461-4. PubMed ID: 23457809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Zealand women's experience during their first year of Jadelle® contraceptive implant.
    Roke C; Roberts H; Whitehead A
    J Prim Health Care; 2016 Mar; 8(1):13-9. PubMed ID: 27477370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with Norplant at a Nigerian teaching hospital.
    Mutihir JT; Aisien AO; Ujah IA
    East Afr Med J; 2010 Nov; 87(11):456-60. PubMed ID: 23457808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subdermal progestin implant contraception.
    Darney PD
    Curr Opin Obstet Gynecol; 1991 Aug; 3(4):470-6. PubMed ID: 1908716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implanon sub-dermal implants: a 10-month review of acceptability in Jos, North-Central Nigeria.
    Mutihir JT; Daru PH
    Niger J Clin Pract; 2008 Dec; 11(4):320-3. PubMed ID: 19320403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contraceptive implants.
    Ladipo O; Coutinho EM
    Curr Opin Obstet Gynecol; 1994 Dec; 6(6):564-9. PubMed ID: 7893965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norplant-2 subdermal contraceptive system: experience in Taiwan.
    Lee TY; Yang YS; Tseng LH; Ko TM; Hsu MC; Chuang SM
    J Formos Med Assoc; 1993 May; 92(5):446-50. PubMed ID: 8104598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of safety, efficacy, and acceptability of NORPLANT implants in Sri Lanka.
    Basnayake S; Thapa S; Balogh SA
    Stud Fam Plann; 1988; 19(1):39-47. PubMed ID: 3129828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contraception with levonorgestrel subdermal implants (Norplant) in Benin-City, Nigeria: a 12-year review.
    Aisien AO
    Afr J Reprod Health; 2007 Apr; 11(1):90-7. PubMed ID: 17982951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo release of levonorgestrel from Sino-implant (II) — an innovative comparison of explant data.
    Callahan RL; Taylor D; Jenkins DW; Owen DH; Cheng L; Cancel AM; Dorflinger LJ; Steiner MJ
    Contraception; 2015 Oct; 92(4):350-5. PubMed ID: 26142619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian Contraception Consensus (Part 3 of 4): Chapter 7--Intrauterine Contraception.
    Black A; Guilbert E; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman W; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; Mansouri S
    J Obstet Gynaecol Can; 2016 Feb; 38(2):182-222. PubMed ID: 27032746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levonorgestrel release rates measured through analysis of two-rod contraceptive explants.
    Fuchs R; Taylor D; Jenkins DW; Brache V; Luo D; Dorflinger LJ; Steiner MJ
    Contracept X; 2020; 2():100039. PubMed ID: 32995746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NORPLANT contraceptive implants advancing.
    Segal SJ
    Netw Res Triangle Park N C; 1984; 5(3):1-3. PubMed ID: 12279797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of early implant discontinuation among low-income women.
    Kalmuss D; Davidson AR; Cushman LF; Heartwell S; Rulin M
    Fam Plann Perspect; 1996; 28(6):256-60. PubMed ID: 8959415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.